The liver disease non-alcoholic steatohepatitis (NASH) has become a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. The race is now to develop the first effective pharmacotherapy to treat it.
Dr Sabina Heinz and Victoria Allan
Advertisement
Dr Sabina Heinz, Virology & Liver Diseases Therapy Monitors, Ipsos Healthcare. (T +44 20 3059 5298 E: Sabina.heinz@ipsos.com)Victoria Allan, Cardiovascular/Respiratory Therapy Monitors, Ipsos Healthcare
Articles by Dr Sabina Heinz and Victoria Allan
Advertisement
Latest Updated Articles
- Who Will Win the Race to Treat NASH?
Published: April 26th 2016 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
3
Merck to Acquire Cidara for $9.2 Billion
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
